I couldnt imagine a vet only buyer would expect to have the price inflated by possible human outcomes.
Two separate addressable markets.
Agree it will make the drug overall more valuable, I can't imagine it would materially push a canine deal up.
Let's hope PAA can go on to sell each indication for hundreds of millions. Initially it'd be nice to land a dog deal that prevents further dilution and also also speeding up of other trials.
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1333
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.005(2.22%) |
Mkt cap ! $95.68M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 21.5¢ | $67.71K | 309.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 135000 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 301664 | 8 |
View Market Depth
| Last trade - 10.56am 18/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |